Get the Stockscreener App
1.83
0.54%
-0.01
After Hours:
1.82
-0.01
-0.55%
Fortress Biotech Inc stock is traded at $1.83, with a volume of 515.67K.
It is down -0.54% in the last 24 hours and down -1.08% over the past month.
Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development. It derives the majority of its revenues from Dermatology segment. Its subsidiaries also operate in biotechnology, pharmaceutical, oncology, therapeutics sectors.
See More
Previous Close:
$1.84
Open:
$1.83
24h Volume:
515.67K
Relative Volume:
0.88
Market Cap:
$50.66M
Revenue:
$80.97M
Net Income/Loss:
$-78.31M
P/E Ratio:
-0.1232
EPS:
-14.85
Net Cash Flow:
$-129.56M
1W Performance:
+16.56%
1M Performance:
-1.08%
6M Performance:
-2.14%
1Y Performance:
-14.49%
1-Day Range:
$1.80
$1.87
1-Week Range:
$1.55
$1.87
52-Week Range:
$1.355
$4.43
Fortress Biotech Inc Stock (FBIO) Company Profile
Name
Fortress Biotech Inc
Sector
Industry
Phone
781-652-4500
Address
1111 KANE CONCOURSE, BAY HARBOR ISLANDS, NY
Compare FBIO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FBIO
Fortress Biotech Inc
|
1.83 | 50.66M | 80.97M | -78.31M | -129.56M | -14.85 |
|
VRTX
Vertex Pharmaceuticals Inc
|
464.56 | 119.70B | 10.63B | -479.80M | -1.35B | 13.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
754.87 | 82.75B | 13.85B | 4.65B | 3.32B | 35.06 |
|
ARGX
Argen X Se Adr
|
614.59 | 36.73B | 1.86B | -40.29M | -1.28B | -4.16 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.74 | 32.53B | 2.09B | -332.26M | 16.06M | -4.14 |
|
BNTX
Biontech Se Adr
|
120.72 | 28.50B | 3.30B | -501.07M | 1.03B | 11.54 |
Fortress Biotech Inc Stock (FBIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-15-24 | Resumed | ROTH MKM | Buy |
| Aug-04-22 | Initiated | Ladenburg Thalmann | Buy |
| Oct-02-20 | Initiated | The Benchmark Company | Buy |
| Dec-18-19 | Initiated | B. Riley FBR | Buy |
| Feb-28-18 | Initiated | B. Riley FBR, Inc. | Buy |
| Jul-11-17 | Initiated | Rodman & Renshaw | Buy |
| Mar-22-17 | Initiated | JMP Securities | Mkt Outperform |
| Oct-03-16 | Initiated | ROTH Capital | Buy |
View All
Fortress Biotech Inc Stock (FBIO) Latest News
Fortress Biotech, Inc. (NASDAQ:FBIO) Shares Sold by GSA Capital Partners LLP - Defense World
FBIOP.PFD (Fortress Biotech) Earnings Yield % : N/A% (As of Nov. 23, 2024) - GuruFocus.com
(FBIOP) Trading Signals - Stock Traders Daily
Fortress Biotech (FRA:CNB0.PFD) Total Liabilities : €125.98 Mil (As of Sep. 2024) - GuruFocus.com
Certain Common Stock of Fortress Biotech, Inc. are subject to a Lock-Up Agreement Ending on 22-NOV-2024. - Marketscreener.com
Certain Warrants of Fortress Biotech, Inc. are subject to a Lock-Up Agreement Ending on 22-NOV-2024. - Marketscreener.com
Fortress Biotech (FRA:CNB1) Capex-to-Operating-Cash-Flow : 0.00 (As of Sep. 2024) - GuruFocus.com
Fortress Biotech price target raised to $15 from $13 at Roth MKM - TipRanks
Fortress Biotech price target lowered to $4 from $5 at Alliance Global Partners - TipRanks
Fortress Biotech price target raised to $26 from $24 at H.C. Wainwright - TipRanks
Fortress Biotech (FRA:CNB1) Total Inventories : €9.00 Mil (As of Jun. 2024) - GuruFocus.com
Fortress Biotech Third Quarter 2024 Earnings: Misses Expectations - Yahoo Finance
Fortress Biotech: Q3 Earnings Snapshot - mySA
Fortress Biotech Inc. (FBIOP) Quarterly 10-Q Report - Quartzy
Fortress Biotech’s Q3 2024 Earnings and FDA Milestone - TipRanks
Fortress Biotech Q3 2024 Earnings: EPS Loss of $0.76 Beats Estimate, Revenue of $14.63M Misses Expectations - GuruFocus.com
Fortress Biotech, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Fortress Biotech Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights - GlobeNewswire
Avenue Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights - GlobeNewswire
Avenue Therapeutics Reports $3.1M Q3 Loss, Advances Key Clinical Trials Pipeline | ATXI Stock News - StockTitan
Mustang Bio gets extension for Nasdaq compliance By Investing.com - Investing.com South Africa
Checkpoint Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Updates - GlobeNewswire
Checkpoint Therapeutics Sets FDA Review Date, Secures $9.2M Funding Boost Amid Q3 Loss | FBIO Stock News - StockTitan
Journey Medical's Mixed Q3: FDA Win for Rosacea Drug Despite Revenue Dip | FBIO Stock News - StockTitan
Mustang Bio gets extension for Nasdaq compliance - Investing.com
Mustang Bio Receives Positive Listing Determination from Nasdaq - The Manila Times
Mustang Bio Secures Critical Nasdaq Extension, Faces January 2025 Deadline for $1 Compliance | MBIO Stock News - StockTitan
Where are the Opportunities in (FBIOP) - Stock Traders Daily
Mustang Bio gains FDA Orphan Drug Status for glioma treatment - Investing.com India
Mustang Bio Granted Orphan Drug Designation by U.S. FDA for - GlobeNewswire
Mustang Bio gains FDA Orphan Drug Status for glioma treatment By Investing.com - Investing.com UK
Journey Medical Corporation Announces U.S. FDA Approval of Emrosi™ (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the Treatment of Rosacea - GlobeNewswire
How To Trade (FBIOP) - Stock Traders Daily
Fortress Biotech Insiders Placed Bullish Bets Worth US$4.49m - Yahoo Finance
Biotech Stocks Facing FDA Decision In November 2024 - RTTNews
Fortress Biotech, Inc.'s (NASDAQ:FBIO) Shares Bounce 36% But Its Business Still Trails The Industry - Simply Wall St
Mustang Bio, Inc. Appoints David Jin as A Member of the Board - Marketscreener.com
Highbridge Capital Management's Strategic Acquisition of Fortress Biotech Shares - Yahoo Finance
Highbridge Capital Management's Strategic Acquisition of Fortres - GuruFocus.com
Journey Medical Corporation Announces DFD-29 Data Presented at 44th Fall Clinical Dermatology Conference - GlobeNewswire
Mustang Bio secures $4 million from warrant exercises - Investing.com India
Mustang Bio secures $4 million from warrant exercises By Investing.com - Investing.com South Africa
Fortress Biotech Inc Stock (FBIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Fortress Biotech Inc Stock (FBIO) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| ROSENWALD LINDSAY A MD | President, CEO & Chairman |
Jul 11 '24 |
Buy |
7.48 |
5,000 |
37,418 |
127,500 |
| Jin David | Chief Financial Officer |
Jul 10 '24 |
Buy |
7.50 |
500 |
3,750 |
500 |
| ROSENWALD LINDSAY A MD | President, CEO & Chairman |
Jul 09 '24 |
Buy |
7.39 |
5,000 |
36,971 |
122,500 |
| ROSENWALD LINDSAY A MD | President, CEO & Chairman |
Jul 08 '24 |
Buy |
7.35 |
5,000 |
36,764 |
117,500 |
| ROSENWALD LINDSAY A MD | President, CEO & Chairman |
Jun 28 '24 |
Buy |
1.64 |
20,000 |
32,724 |
2,893,905 |
| ROSENWALD LINDSAY A MD | President, CEO & Chairman |
May 16 '24 |
Buy |
1.76 |
10,000 |
17,589 |
2,873,905 |
| Klein Dov | Director |
May 20 '24 |
Sale |
1.89 |
10,000 |
18,900 |
53,400 |
| ROSENWALD LINDSAY A MD | President, CEO & Chairman |
Jan 05 '24 |
Buy |
2.38 |
50,000 |
118,770 |
2,863,905 |
1.35%
0.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):